NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Positive

AI Analysis

Summary

NovaGo Therapeutics closed a USD 30 million Series B financing round led by Neurimmune and Pureos to advance a proof-of-concept study in acute spinal cord injury, supplemented by non-dilutive funding from patient foundations.

Clinical Trial Data

Phase

proof-of-concept

Importance:6/10

Sentiment:

0.70

financingSeries Bspinal cord injuryclinical trial

Read the original article

Published by PR Newswire Pharma on September 2, 2026 10:00 AM

Read Original